Simon Jones

Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom.

Oxonica Ltd. is an advanced materials business, which engages in licensing of patents related to nanomaterials. The company was founded in 1999 and is headquartered in Birmingham, the United Kingdom.

Vodafone UK Ltd. provides mobile telecommunications services. Its services include information on services, pricing, roaming, and coverage. Its subscribers include corporate and individual consumers. Vodafone has launched 3G service in the 2004 and is responsible for wireless operations of Vodafone Group in UK. The company is headquartered in Newbury, UK.

Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom.